{
    "clinical_study": {
        "@rank": "41734", 
        "arm_group": [
            {
                "arm_group_label": "Teriparatide", 
                "arm_group_type": "Active Comparator", 
                "description": "daily subcutaneous injection of teriparatide 20\u00b5g for three months"
            }, 
            {
                "arm_group_label": "Placebo Teriparatide", 
                "arm_group_type": "Placebo Comparator", 
                "description": "daily subcutaneous teriparatide placebo injection"
            }, 
            {
                "arm_group_label": "Denosumab", 
                "arm_group_type": "Active Comparator", 
                "description": "one subcutaneous injection of denosumab"
            }, 
            {
                "arm_group_label": "Placebo Denosumab", 
                "arm_group_type": "Active Comparator", 
                "description": "one subcutaneous injection of denosumab placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The etiology of bone marrow edema (BME) is still uncertain. Several studies report\n      therapeutic success with antiresorptive drugs.\n\n      This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME"
        }, 
        "brief_title": "Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bone Marrow Oedema Syndrome", 
            "High Turnover Bone Disease", 
            "Quality of Life"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bone Diseases", 
                "Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily\n      teriparatide sc for three months or placebo.\n\n      MRI examinations at baseline and after three months will be performed. Serum bone turnover\n      markers will be evaluated as well as QoL questionnaires."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  MRI diagnosed bone marrow edema\n\n        Exclusion Criteria:\n\n          -  any prior antiresorptive or osteoanabolic treatment\n\n          -  any prior therapy with strontium ranelate\n\n          -  Hyper-/hypocalcemia\n\n          -  malignancies\n\n          -  pregnancy\n\n          -  and contraindication against denosumab or teriparatide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734824", 
            "org_study_id": "Vinforce-012", 
            "secondary_id": "Bone marrow edema"
        }, 
        "intervention": [
            {
                "arm_group_label": "Denosumab", 
                "description": "sc RANKL-inhibitor", 
                "intervention_name": "Denosumab", 
                "intervention_type": "Drug", 
                "other_name": "Prolia"
            }, 
            {
                "arm_group_label": "Teriparatide", 
                "description": "daily subcutaneous injection of teriparatide", 
                "intervention_name": "Teriparatide", 
                "intervention_type": "Drug", 
                "other_name": "PTH 1-34"
            }, 
            {
                "arm_group_label": "Placebo Denosumab", 
                "description": "one subcutaneous injection denosumab placebo", 
                "intervention_name": "Placebo Denosumab", 
                "intervention_type": "Drug", 
                "other_name": "Prolia"
            }, 
            {
                "arm_group_label": "Placebo Teriparatide", 
                "description": "daily subcutaneous placebo injection", 
                "intervention_name": "Placebo Teriparatide", 
                "intervention_type": "Drug", 
                "other_name": "PTH 1-34"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Teriparatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "bone marrow edema, denosumab, PTH 1-84", 
        "lastchanged_date": "August 27, 2013", 
        "link": {
            "description": "non-profit web page", 
            "url": "http://www.vinforce.at"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1060"
                }, 
                "name": "Medical University Vienna - St. Vincent Hospital"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "4", 
        "official_title": "Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo", 
        "overall_official": {
            "affiliation": "Medical University of Vienna", 
            "last_name": "Christian Muschitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MRI examination, fasting serum levels of bone turnover markers, QoL-questionnaire, VAS score", 
            "measure": "Reduction/termination of bone marrow edema with antiresorptive and osteoanabolic drugs", 
            "safety_issue": "Yes", 
            "time_frame": "baseline - month 1 -  month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734824"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Dr. Christian Muschitz", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}